The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure

Journal of the American College of Cardiology

Volumn 65, Issue 10, 2015, Pages 1029-1041

  Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

hypertension; natriuretic peptide; renin

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ADRENOMEDULLIN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ENKEPHALINASE INHIBITOR; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; OMAPATRILAT; PEPTIDASE; SACUBITRIL; SARALASIN; UNCLASSIFIED DRUG; VALSARTAN; VASOPEPTIDASE; VASOPEPTIDASE INHIBITOR; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

ARTERIAL STIFFNESS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENZYME DEGRADATION; ENZYME INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; ART; DRUG DESIGN; HISTORY; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; DRUG DESIGN; HEART FAILURE; HISTORY, 20TH CENTURY; HUMANS; NEPRILYSIN; PHYSIOLOGY; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; TETRAZOLES;

EID: 84924402407     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.01.033     Document Type: Review

References (116)

1. H.W. Turnbull The Correspondence of Isaac Newton Volume 1 1959 Cambridge University Press Cambridge 416
2. PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results. Novartis press release. March 31, 2014. Available at: http://www.novartis.com/newsroom/media-releases/en/2014/1772754.shtml. Accessed January 19, 2015.
3. J.J.V. McMurray, M. Packer, A.S. Desai for the PARADIGM-HF Committees Investigators Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail 15 2013 1062 1073
4. J.J.V. McMurray, M. Packer, A.S. Desai for the PARADIGM-HF Committees and Investigators Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail 16 2014 817 825
5. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
6. J.J.V. McMurray, M. Packer, and A.S. Desai Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
7. M. Jessup Neprilysin inhibition - a novel therapy for heart failure N Engl J Med 371 2014 1062 1064
8. C.A. Sacks, J.A. Jarcho, and G.D. Curfman Paradigm shifts in heart-failure therapy - a timeline N Engl J Med 371 2014 989 991
9. R. Tigerstedt, and P.G. Bergman Niere und Kreislauf Scand Arch Physiol 8 1898 223 271
10. L.S. Marks, and M.H. Maxwell Tigerstedt and the discovery of renin. An historical note Hypertension 1 1979 384 388
11. H. Goldblatt, J. Lynch, and R.F. Hanzal Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia J Exp Med 59 1934 347 379
12. E. Braun-Menendez, J.C. Fasciolo, and L.F. Leloir The substance causing renal hypertension J Physiol 98 1940 283 298
13. I.H. Page, and O.M. Helmer A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator J Exp Med 71 1940 29 42
14. R.M. Carey, and H.M. Siragy Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation Endocrine Rev 24 2003 261 271
15. S.H. Ferreira A bradykinin-potentiating factor (BPF) present in the venom of Bothrops Jararaca Br J Pharm 24 1965 163 169
16. S.H. Ferreira, L.H. Greene, and V.A. Alabaster Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme Nature 225 1970 379 380
17. H. Gavras, H.R. Brunner, and J.H. Laragh An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients N Engl J Med 291 1974 817 821
18. C. Curtiss, J.N. Cohn, and T. Vrobel Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure Circulation 58 1978 763 770
19. A.L. Blumberg, S.E. Denny, and G.R. Marshall Blood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandins Am J Physiol 232 1977 H305 H310
20. M.A. Ondetti, B. Rubin, and D.W. Cushman Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents Science 196 1977 441 444
21. H. Gavras, H.R. Brunner, and G.A. Turini Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man N Engl J Med 298 1978 991 995
22. J.M. Pfeffer, M.A. Pfeffer, and E. Braunwald Influence of chronic captopril therapy on the infarcted left ventricle of the rat Circ Res 57 1985 84 95
23. M.A. Pfeffer, E. Braunwald, and L.A. Moyé Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 1992 669 677
24. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
25. G.R. Marshall, W. Vine, and P. Needlemann A specific competitive inhibitor of angiotensin II Proc Natl Acad Sci U S A 67 1970 1624 1630
26. Carini D, Duncia JV. Angiotensin II receptor blocking imidazoles. European Patent Application 025331e; 1988.
27. P.B. Timmermans, D.J. Carini, and A.T. Chiu Angiotensin II receptor antagonists: From discovery to antihypertensive drugs Hypertension 18 1991 III136 III142
28. J.N. Cohn, G. Tognoni for the Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
29. C.M. Kagawa, F.M. Sturtevant, and C.G. Van Arman Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone J Pharm Exp Ther 126 1959 123 130
30. B. Pitt, F. Zannad, W.J. Remme for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
31. B. Kisch Electron microscopy of the atrium of the heart Exp Med Surg 14 1956 99 112
32. A.J. de Bold, J.J. Raymond, and S.A. Bencosme Atrial specific granules of the rat heart: light microscopic staining and histochemical reactions J Histochem Cytochem 26 1978 1094 1102
33. A.J. de Bold Heart atria granularity effects of changes in water-electrolyte balance Exper Biol Med 161 1979 508 511
34. A.J. de Bold, H.B. Borenstein, and A.T. Veress A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats Life Sci 28 1981 89 94
35. A.J. de Bold Atrial natriuretic factor: a hormone produced by the heart Science 230 1985 767 770
36. T. Ogawa, and A.J. de Bold The heart as an endocrine organ Endocr Connect 3 2014 R31 R44
37. E. Braunwald, D.C. Harrison, and C.A. Chidsey The heart as an endocrine organ Am J Med 36 1964 1 4
38. T. Sudoh, K. Kangawa, and N. Minamino A new natriuretic peptide in porcine brain Nature 332 1988 78 81
39. M. Mukoyama, K. Nakao, and K. Hosoda Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide J Clin Invest 87 1991 1402 1412
40. T. Sudoh, N. Minamino, and K. Kangawa C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain Biochem Biophys Res Comm 168 1990 863 870
41. M. Kuhn Molecular physiology of natriuretic peptide signalling Basic Res Cardiol 99 2004 76 82
42. E.R. Levin, D.G. Gardner, and W.K. Sampson Natriuretic peptides N Engl J Med 339 1998 321 328
43. J.C. Burnett Jr., P. Granger, and T.J. Opgenorth Effects of synthetic atrial natriuretic factor on renal function and renin release Am J Physiol 247 1984 F863 F866
44. K. Atarashi, P.J. Mulrow, and R. Franco-Saenz Effects of atrial peptides on aldosterone production J Clin Invest 76 1985 1807 1811
45. S. Mangiafico, L.C. Costello-Boerrigter, and I.A. Andersen Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics Eur Heart J 34 2013 886 893c
46. P.M. McKie, A. Cataliotti, and G. Boerrigter A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension Hypertension 56 2010 1152 1159
47. H. Nakagawa, H. Oberwinkler, and V.O. Nikolaev Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation Circ Heart Fail 7 2014 814 821
48. A.J. Stingo, A.L. Clavell, and L.L. Aarhus Cardiovascular and renal actions of C-type natriuretic peptide Am J Physiol 262 1992 H308 H312
49. J.C. Burnett Jr., P.C. Kao, and D.C. Hu Atrial natriuretic peptide elevation in congestive heart failure in the human Science 231 1986 1145 1147
50. H.K. Gaggin, and J.L. Januzzi Jr. Biomarkers and diagnostics in heart failure Biochim Biophys Acta 1832 2013 2442 2450
51. L.B. Daniels, and A.S. Maisel Natriuretic peptides J Am Coll Cardiol 50 2007 2357 2368
52. R.W. Troughton, C.M. Frampton, and H.P. Brunner-La Rocca Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis Eur Heart J 35 2014 1559 1567
53. N. Hata, Y. Seino, and T. Tsutamoto Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study Circ J 72 2008 1787 1793
54. C.M. O'Connor, R.C. Starling, and A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
55. K. Kitamura, K. Kangawa, and M. Kawamoto Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma Biochem Biophys Res Comm 192 1993 553 560
56. J.P. Hinson, S. Kapas, and D.M. Smith Adrenomedullin, a multifunctional regulatory peptide Endocrine Rev 21 2000 138 167
57. N. Nagaya, T. Satoh, and T. Nishikimi Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure Circulation 101 2000 498 503
58. M. Jougasaki, C.M. Wei, and L.J. McKinley Elevation of circulating and ventricular adrenomedullin in human congestive heart failure Circulation 92 1995 286 289
59. N.G. Morgenthaler, J. Struck, and C. Alonso Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay Clin Chem 51 2005 1823 1829
60. A. Maisel, C. Mueller, and R. Nowak Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial J Am Coll Cardiol 55 2010 2062 2076
61. L.R. Potter Natriuretic peptide metabolism, clearance and degradation FEBS J 278 2011 1808 1817
62. C.J. Charles, E.A. Espiner, and M.G. Nicholls Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep Am J Physiol 271 1996 R373 R380
63. M.A. Kerr, and A.J. Kenny The purification and specificity of a neutral endopeptidase from rabbit kidney brush border Biochem J 137 1974 477 488
64. S.L. Stephenson, and A.J. Kenny The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11 Biochem J 243 1987 183 187
65. S. Kuruppu, N.W. Rajapakse, and D. Minond Production of soluble Neprilysin by endothelial cells Biochem Biophys Res Comm 446 2014 423 427
66. K. Nakao, A. Sugawara, and N. Morii The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects Eur J Clin Pharmacol 31 1986 101 103
67. O.J. Lisy, M. Jougasaki, and J.A. Schirger Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin Am J Physiol 275 1998 F410 F414
68. Y. Liu, C. Studzinski, and T. Beckett Circulating neprilysin clears brain amyloid Mol Cell Neurosci 45 2010 101 107
69. B.P. Roques, M.C. Fournie-Zaluski, and E. Soroca The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice Nature 288 1980 286 288
70. E.J. Sybertz, P.J.S. Chiu, and S. Vemulapalli SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats J Pharm Exp Ther 250 1989 624 631
71. D.B. Northridge, A.G. Jardine, and C.T. Alabaster Effects of UK 69 578: a novel atriopeptidase inhibitor Lancet 2 1989 591 593
72. G.M. Ksander, R.D. Ghai, and R. deJesus Dicarboxylic acid dipeptide neutral endopeptidase inhibitors J Med Chem 38 1995 1689 1700
73. M.T. Rademaker, C.J. Charles, and E.A. Espiner Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure Clin Sci (Lond) 91 1996 283 291
74. H.H. Chen, J.A. Schirger, and W.L. Chau Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure Circulation 100 1999 2443 2448
75. F.L. Martin, T.L. Stevens, and A. Cataliotti Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure Kidney Int 67 2005 1723 1730
76. T. Munzel, S. Kurz, and J. Holtz Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure Circulation 86 1992 1089 1098
77. J.G. Cleland, K. Swedberg for the International Ecadotril Multi-centre Dose-ranging Study Investigators Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure Lancet 351 1998 1657 1658
78. J.E. O'Connell, A.G. Jardine, and G. Davidson Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension J Hypertens 10 1992 271 277
79. N.L.M. Cruden, K.A.A. Fox, and C.A. Ludlam Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition Hypertension 44 2004 913 918
80. G. McDowell, W. Coutie, and C. Shaw The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides Br J Clin Pharmacol 43 1997 329 332
81. C.J. Ferro, J.C. Spratt, and W.G. Haynes Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 1998 2323 2330
82. S. Ando, M.A. Rahman, and G.C. Butler Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin Hypertension 26 1995 1160 1166
83. A.A. Seymour, J.N. Swerdel, and B. Abboa-Offei Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme J Cardiovasc Pharmacol 17 1991 456 465
84. N.C. Trippodo, M. Fox, and T.M. Monticello Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril J Cardiovasc Pharmacol 34 1999 782 790
85. A.A. Seymour, M.M. Asaad, and V.M. Lanoce Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure J Pharmacol Exp Ther 266 1993 872 883
86. M.T. Rademaker, C.J. Charles, and C.J. Espiner Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II J Cardiovasc Pharm 31 1998 116 125
87. M.C. Fournie-Zaluski, P. Coric, and S. Turcaud New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension J Med Chem 37 1994 1070 1083
88. J.A. Robl, C.Q. Sun, and J. Stevenson Dual metalloproteinase inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase J Med Chem 40 1997 1570 1577
89. V.M. Campese, K.C. Lasseter, and C.M. Ferrario Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients Hypertension 38 2001 1342 1348
90. J.L. Rouleau, M.A. Pfeffer, and D.J. Stewart Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure. IMPRESS randomised trial Lancet 356 2000 615 620
91. R. Tabrizchi Omapatrilat. Bristol-Myers Squibb Curr Opin Investig Drugs 2 2001 1414 1422
92. M. Packer, R.M. Califf, and M.A. Konstam Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
93. J.B. Kostis, M. Packer, and H.R. Black Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
94. N.L. Cruden, K.A. Fox, and C.A. Ludlam Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition Hypertension 44 2004 913 918
95. J. Gu, A. Noe, and P. Chandra Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor. (ARNi) J Clin Pharmacol 50 2010 401 414
96. D.J. Campbell Vasopeptidase inhibition: a double-edged sword? Hypertension 41 2003 383 389
97. Webb RL, Ksander GM. Pharmaceutical compositions comprising valsartan and NEP inhibitors. International Patent Application PCT/EP03/00415, 2003.
98. L. Feng, P.H. Karpinski, and P. Sutton LCZ696: a dual-acting sodium supramolecular complex Tetrahedron Lett 53 2012 275 276
99. L.M. Ruilope, A. Dukat, and M. Bohm Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
100. K. Kario, N. Sun, and F.T. Chiang Efficacy and safety of LCZ696. A first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study Hypertension 63 2014 698 705
101. S.D. Solomon, M. Zile, B. Pieske for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
102. M. Packer, J.J.V. McMurray, A.S. Desai for the PARADIGM-HF Investigators and Coordinators Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 2015 54 61
103. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
104. P. Ruggenenti, A. Perna, and G. Gherardi Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 1999 359 364
105. G.W. Lipkin, A.B. Dawnay, and S.M. Harwood Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure Kidney Int 52 1997 792 801
106. A. Benigni, C. Zoja, and C. Zatelli Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy Kidney Int 66 2004 1959 1965
107. B.J. Davis, C.I. Johnston, and L.M. Burrell Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy Diabetologia 46 2003 961 971
108. P. Judge, R. Haynes, and M.J. Landray Neprilysin inhibition in chronic kidney disease Nephrol Dial Transplant 2014 Aug 18 [E-pub ahead of print]
109. B. Williams, J.R. Cockcroft, and K. Kario Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker Measuring arterial sTiffness int he eldERly (PARAMETER) study BMJ Open 4 2014 e004254
110. D. Gallagher, A. Adji, and M.H. O'Rourke Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform Am J Hypertens 17 2004 1059 1067
111. M.L. Ford, L.A. Tomlinson, and T.P. Chapman Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4 Hypertension 55 2010 1110 1115
112. H.L. Booysen, G.R. Norton, and M.J. Maseko Aortic, but not brachial blood pressure category enhances the ability to identify target organ changes in normotensives J Hypertens 31 2013 1124 1130
113. M.J. Roman, P.M. Okin, and J.R. Kizer Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study J Hypertens 28 2010 384 388
114. G.F. Mitchell, J.L. Izzo Jr., and Y. Lacourciere Omaptrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study Circulation 105 2002 2955 2961
115. S. Wassertheurer, J. Kropf, and T. Weber A new oscillometric method for pulse wave analysis: comparison with a common tonometric method J Hum Hypertens 24 2010 498 504
116. O. Vardeny, R. Miller, and S.D. Solomon Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure J Am Coll Cardiol HF 2 2014 663 670